Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in neutrophils | 0.75 |
| chemistry Open Targets | hard to drug | 0.40 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9703
Sealed predictions
- AGAP2 in dopamine neurons, braak-0.29 (p 0.457) → -0.35 (p 0.362)receipt 9709
Swarm cases
receipt 9709: AGAP2 in dopamine neurons, braak
- power
- full sample -0.33 (p 0.185, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.232, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.53 (p 0.025, n 18). not the mix.
- skeptic
- leave-one-out range -0.44 to -0.24, sign flips 0; without severely affected donors -0.33 (p 0.185, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AGAP2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts